Shree Ganesh Remedies Ltd Business Overview - SOIC x StockScans Report

as of Jul 2026

Business segments

A single engine with two faces - a pharmaceutical-intermediates heritage that still provides the bulk of revenue, and a specialty-chemicals practice that is rapidly taking over, both delivered through the same contract-research-and-manufacturing model and the same set of reaction technologies.

1. Pharmaceutical intermediates: the legacy molecule factory

The company makes the chemical building blocks for generic drugs - anti-psychotics, anti-depressants, cancer therapies - and sells them to API manufacturers who turn them into finished medicines.

2. Specialty and fine chemicals: the growth engine moving up the value chain

What began as an extension into agrochemical and polymer ingredients has become the company’s main growth story, with project sizes swelling and customers upgrading SGRL from backup supplier to preferred partner.

3. Contract research and manufacturing (CRAMS/CDMO): the business model that ties it together

Every product the company sells - whether a pharma intermediate or a specialty chemical - is made under a contract-research or contract-manufacturing agreement where the customer pays for development work and then for each unit produced.

Chemistry and technology backbone

The company’s real moat is not any single product but its ability to perform a wide range of difficult, hazardous and tightly controlled chemical reactions under one roof - a breadth that most peers cannot match.

Manufacturing infrastructure

Two adjacent plants in Gujarat’s chemical corridor, plus a greenfield site under construction at Dahej, give the company the reactor capacity and environmental permits to handle everything from gram-scale trials to hundred-tonne commercial campaigns.

Group structure and partners

SGRL is a standalone listed entity with no operating subsidiaries, a tightly held promoter group, and a history of using temporary acquisition structures solely to secure land.